About Jasper

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. We are focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.

JSP191, our lead compound, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic stem cell transplantation or gene therapy.

Our novel engineered hematopoietic stem cells (eHSCs) platform is intended to address the limitations of transplant grafts and unlock the potential of stem cells, potentially expanding the number of patients who could benefit from allogeneic and autologous gene edited hematopoietic stem cell therapy.

Our History

Jasper Therapeutics was founded by Dr. Judith Shizuru, a Stanford professor, and Dr. Susan Prohaska, a Stanford-trained immunology and stem cell scientist and drug developer, with the goal of bringing curative hematopoietic stem cell transplantation and gene therapies to more people by making them safer and more effective. Building on niche-clearing technology from Stanford, Dr. Shizuru initiated a clinical program funded by the California Institute for Regenerative Medicine (CIRM) with $23M in grant support to safely condition patients prior to hematopoietic stem cell transplantation.

Jasper unites technologies from Stanford University and Amgen with cutting-edge science and expertise in hematopoietic stem cell transplantation, stem cell biology, oncology and drug development. Jasper has acquired worldwide rights to JSP191 from Amgen, which originally discovered JSP191 (formerly AMG191), as well as translational science and materials from Stanford University.

Jasper Therapeutics was launched with $50M in Series A financing. Abingworth LLP and Qiming Venture Partners USA served as lead investors, with further investment from Surveyor Capital (a Citadel company), Alexandria Venture Investments, LLC and Roche Venture Fund.